By Fineline Cube 
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has secured marketing approval from the National Medical Products Administration (NMPA) for its polylactic acid facial filler. Developed by its subsidiary MEIYOUNG, the product is classified as a Category III medical device and is indicated for the correction of moderate to severe nasolabial folds.
Product Overview
The polylactic acid facial filler is a synthetic dermal filler designed to stimulate the skin to produce new collagen. It features stable biodegradation properties, making it a safe and effective option for patients seeking long-lasting results.
Mechanism of Action
Upon injection, the product provides an immediate filling effect to reduce the appearance of nasolabial folds. Over time, the poly-L-lactic acid (PLLA) microspheres within the filler continuously stimulate the injection site, promoting collagen production. This results in long-term skin regeneration and sustained improvement in skin texture and appearance.-Fineline Info & Tech